|
Status |
Public on Dec 19, 2020 |
Title |
Profiling non-small cell lung carcinoma cell line PC9 treated with erlotinib |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. To be able to better understand the differences in response between individual cells, we performed treatment of PC9 cells grown in cell culture with erlotinib followed by Drop-seq. We were able to clearly distinguish cells that were treated with the drug for five different time points from untreated cells, and we discovered different cell populations within the treated cells, likely reflecting heterogeneity of drug resistant cells. We were able to identify specific biomarkers, as preferentially expressed genes, for each cell population. The results of our study will address preexisting and acquired drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC.
|
|
|
Overall design |
Examining drug resistant cell populations using single cell RNA-seq
|
|
|
Contributor(s) |
Benevolenskaya EV, Aissa AF, Islam AB |
Citation(s) |
33712615 |
NIH grant(s) |
Grant ID |
Grant title |
Affiliation |
Name |
R01 CA211095 |
Role of KDM5A in pRB-mediated differentiation |
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
Elizaveta V. Benevolenskaya |
|
|
Submission date |
Jul 25, 2019 |
Last update date |
Mar 22, 2021 |
Contact name |
Elizaveta V Benevolenskaya |
E-mail(s) |
[email protected]
|
Phone |
312-413-8947
|
Organization name |
University of Illinois at Chicago
|
Department |
Biochemistry and Molecular Genetics
|
Street address |
900 S. Ashland Ave.
|
City |
Chicago |
State/province |
IL |
ZIP/Postal code |
60607 |
Country |
USA |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (6)
|
|
This SubSeries is part of SuperSeries: |
GSE149383 |
Drug resistant changes at the level of single cells |
|
Relations |
BioProject |
PRJNA556612 |
SRA |
SRP216361 |